20 Jun '17, 12pm

MDS Trial is now enrolling patients:

Patients with higher-risk MDS failing HMA treatment (targeted patient population) have no approved medical therapy and a short life expectancy (approximately 4-6 months; Bello 2009, Jabbour 2008, Jabbour 2010, Prebet 2011). Once treatment with an HMA has failed prognosis is dismal and thus there is a great unmet medical need to identify novel therapies for these patients. We propose to enroll patients with MDS who have excess blasts (5% to 30% BM blasts), and have progressed during, failed to respond to, are intolerant of, or relapsed after AZA or DAC treatment. Patients’ MDS must be classified as RAEB 1 and RAEB 2 by World Health Organization (WHO) criteria (Appendix 2) or refractory anemia with excess blasts in transformation (RAEB t) based on the French-American-British (FAB) classification (Appendix 3). The primary objective of this study is to to compare the overall s...

Full article: http://www.aamds.org/treatments/clinical-trials/phase-iii...

Tweets

Would you help in this MDS study?

Would you help in this MDS study?

aamds.org 27 Jun '17, 2pm

Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic s...

Spotlight Clinical Trial for AML patients! Chec...

aamds.org 13 Jun '17, 4pm

This is a randomized, multicenter, open-label, Phase 2 study of the oral SINE™ compound selinexor in patients 60 years of ...

Air Force: As many as 135 patients may have bee...

airforcetimes.com 19 Jun '17, 9pm

Improperly-cleaned medical equipment at the clinic at Al Udeid Air Base in Qatar may have exposed as many as 135 patients ...